Seres Therapeutics, Inc. (NASDAQ:MCRB) CEO Eric D. Shaff Sells 12,726 Shares of Stock

Seres Therapeutics, Inc. (NASDAQ:MCRB) CEO Eric D. Shaff sold 12,726 shares of the company’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $0.81, for a total transaction of $10,308.06. Following the completion of the sale, the chief executive officer now directly owns 192,039 shares in the company, valued at approximately $155,551.59. The trade was a 6.21 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Seres Therapeutics Stock Performance

NASDAQ:MCRB opened at $0.83 on Thursday. The company has a market cap of $141.68 million, a price-to-earnings ratio of -3.61 and a beta of 2.11. The stock’s fifty day moving average price is $0.84 and its two-hundred day moving average price is $0.85. Seres Therapeutics, Inc. has a 52-week low of $0.54 and a 52-week high of $1.53.

Hedge Funds Weigh In On Seres Therapeutics

Several large investors have recently made changes to their positions in the company. Virtu Financial LLC increased its position in Seres Therapeutics by 44.8% in the third quarter. Virtu Financial LLC now owns 58,791 shares of the biotechnology company’s stock worth $56,000 after purchasing an additional 18,191 shares during the period. Providence Wealth Advisors LLC grew its position in shares of Seres Therapeutics by 29.2% during the 3rd quarter. Providence Wealth Advisors LLC now owns 98,500 shares of the biotechnology company’s stock worth $93,000 after buying an additional 22,250 shares during the period. Avantax Advisory Services Inc. grew its position in shares of Seres Therapeutics by 170.9% during the 4th quarter. Avantax Advisory Services Inc. now owns 45,179 shares of the biotechnology company’s stock worth $38,000 after buying an additional 28,500 shares during the period. Jane Street Group LLC lifted its holdings in Seres Therapeutics by 181.4% in the fourth quarter. Jane Street Group LLC now owns 58,736 shares of the biotechnology company’s stock valued at $49,000 after buying an additional 37,866 shares during the period. Finally, State Street Corp lifted its holdings in Seres Therapeutics by 12.9% in the third quarter. State Street Corp now owns 383,248 shares of the biotechnology company’s stock valued at $363,000 after buying an additional 43,700 shares during the period. Institutional investors and hedge funds own 59.34% of the company’s stock.

Analysts Set New Price Targets

MCRB has been the topic of several research analyst reports. Canaccord Genuity Group reaffirmed a “buy” rating and set a $10.00 price objective on shares of Seres Therapeutics in a research note on Thursday, November 14th. StockNews.com upgraded Seres Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, February 14th. JPMorgan Chase & Co. lowered Seres Therapeutics from a “neutral” rating to an “underweight” rating in a research note on Thursday, October 24th. Finally, Chardan Capital restated a “buy” rating and issued a $1.25 target price on shares of Seres Therapeutics in a research note on Wednesday, November 13th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $5.08.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.